Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
- Dozens of patients have filed Lawsuits against drugmakers Novo and Eli Lilly, alleging the companies failed to warn users about sudden vision loss from GLP-1s including Ozempic, Wegovy, Mounjaro, and Zepbound.
- Non-Arteritic anterior ischaemic optic neuropathy, or NAION, is a rare condition that can lead to sudden and sometimes permanent vision loss due to lack of blood flow to the optic nerve.
- Research involving more than 159,000 participants with type 2 diabetes found 35 cases of NAION among GLP-1 users compared to 19 in the comparison group; researchers also identified 93 patients with 'Other optic nerve disorders.'
- Similar Lawsuits against Eli Lilly are currently pending, with plaintiffs claiming the company failed to adequately warn patients of risks associated with their weight-loss and diabetes treatments.
- The American Academy of Ophthalmology encourages clinicians and patients to make 'informed choices' regarding GLP-1s, while noting that studies show modest risk but fewer patients experienced sight-threatening complications from diabetes.
67 Articles
67 Articles
What GLP-1 users should know about the potential risk of a rare type of vision loss - Regional Media News
Dozens of Americans have filed personal injury lawsuits against the makers of popular GLP-1 drugs, like Ozempic, Wegovy and Mounjaro, claiming they were not properly warned of the risk of a rare type of sudden vision loss, called nonarteritic anterior ischemic optic neuropathy, or NAION, [...]
Hundreds of lawsuits have been brought in the past 12 months in the United States against manufacturers of GLP-1 drugs.
Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss - NEW YORK TIMES POST
NEWYou can now listen to Fox News articles! Hundreds of consumers are suing the manufacturers of GLP-1 receptor agonists, alleging the medications may increase the risk of a rare form of vision loss. The patients behind the lawsuits allege that the medications caused NAION (nonarteritic anterior ischemic optic neuropathy), according to The Wall Street Journal. [...]
Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
Hundreds of consumers are suing makers of GLP-1 drugs like Ozempic and Wegovy, alleging semaglutide medications may increase the risk of NAION, a rare eye stroke causing vision loss.
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium





















